Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Issuers

PRICED: Almirall E300m 5NC2 sr notes 2.125% at 100

HYC US Market: Commentary - M&AHYC European Market: Commentary - M&AHYC European Market: Deal Flow - General

Almirall SA (ALMSM) EUR300m (up from EUR250m) 144A/Reg S sr notes due 09/30/26 (5y). NC2 (09/30/23) (MWC B+50bp), then at 101.063, 100.531, 100. Equity claw: 2y 40% at 102.125. Ba3/BB- (stable/stable). Via BNP/JPM (B&D) jt glocos/BBVA/BofA/Caixa/Santander jt books. No reg rights. List lux. NY law. Pays March 15 and Sept 15, starting 03/15/22. Settles 09/22 (T+5). Reg S ISIN: XS238816245. IPT: mid 2s.Px talk: 2.25%-2.50%. Launched: EUR300m at 2.125%.

Priced: 2.125% at 100. +276bp vs OBL 0% 10/09/26.

Did investor call at 11am UKT Mon (virtual 1x1s Mon-Weds). Books closed at 12pm UKT today. Recommitments were due by 1pm UKT today. UK afternoon. UOP: to repay its EUR250m 0.25% cvt notes due 12/14/21, and GCP (EUR50m upsize for GCP). Biz: a publicly listed pharmaceutical company that researches, develops, produces and markets a fairly diversified portfolio of in-house developed drugs and in-licensed drugs in therapeutic areas including dermatology, respiratory, gastrointestinal and pain relief. HQ: Barcelona, Spain.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.